학술논문

Ectomesenchymal Chondromyxoid Tumor
Document Type
article
Source
The American Journal of Surgical Pathology. 42(10)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Research
Genetics
Human Genome
Cancer
Aetiology
2.1 Biological and endogenous factors
Actins
Adolescent
Adult
Biomarkers
Tumor
DNA-Binding Proteins
Desmin
Female
Gene Fusion
Genetic Predisposition to Disease
Glial Fibrillary Acidic Protein
Humans
Immunohistochemistry
In Situ Hybridization
Fluorescence
Keratins
Male
Middle Aged
Neoplasms
Connective and Soft Tissue
Phenotype
Retrospective Studies
S100 Proteins
Sequence Analysis
RNA
Tongue Neoplasms
Transcription Factors
Young Adult
ectomesenchymal chondromyxoid tumor
tongue
gene rearrangement
RREB1
MKL2
EWSR1
CREM
Pathology
Clinical sciences
Language
Abstract
Ectomesenchymal chondromyxoid tumor is a rare and benign neoplasm with a predilection for the anterior dorsal tongue. Despite morphologic heterogeneity, most cases are characterized by a proliferation of bland spindle cells with a distinctive reticular growth pattern and myxoid stroma. The immunophenotype of these neoplasms is likewise variable; most cases express glial fibrillary acid protein and S100 protein, with inconsistent reports of keratin and myoid marker expression. The molecular pathogenesis is poorly understood; however, a subset of cases has been reported to harbor EWSR1 gene rearrangement. Following identification of an RREB1-MKL2 fusion gene by RNA Sequencing in an index patient, a retrospective review of additional cases of ectomesenchymal chondromyxoid tumors was performed to better characterize the clinical, immunohistochemical, and molecular attributes of this neoplasm. A total of 21 cases were included in this series. A marked predisposition for the dorsal tongue was confirmed. Most cases conformed to prior morphologic descriptions; however, hypercellularity, hyalinized stroma, and necrosis were rare attributes not previously emphasized. The neoplastic cells frequently coexpressed glial fibrillary acid protein, S100 protein, keratin, smooth muscle actin, and/or desmin; a single case was found to contain significant myogenin expression. An RREB1-MKL2 fusion product was identified in 19 tumors (90%), a single tumor (5%) had an EWSR1-CREM fusion product, and the remaining case lacked any known fusion gene by RNA Sequencing. The latter 2 cases subtly differed morphologically from many in the cohort. This series illustrates that recurrent RREB1-MKL2 fusions occur in most, perhaps all, cases of ectomesenchymal chondromyxoid tumor.